Although anti-PD-1 therapy has shown limited efficacy in DLBCL compared with other B-cell lymphomas, with an ORR of only 6.12% in monotherapy for relapsed/refractory DLBCL, the combination of anti-PD-1 and BTKi has shown significant improvement, with an ORR of 32.69% (20). Here, IBTK is linked to B-cell non-Hodgkin lymphoma.